An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
Research by the Scripps Translational Science Institute (STSI) has found that a small adhesive wireless device worn on the chest for up to two weeks does a better job detecting abnormal and potentially dangerous heart rhythms than the Holter monitor, which is typically used for 24 hours and has been the standard of care for more than 50 years.
In a new study, scientists from University of Copenhagen document a connection between congenital arrhythmia and the bodies' ability to handle sugar. The results can be of vital importance for patients with the disease and for the future treatment of diabetes. The new study has just been published in the scientific journal Diabetes.
Atrial fibrillation, long considered the most common condition leading to an irregular heartbeat, is a growing and serious global health problem, according to the first study ever to estimate the condition's worldwide prevalence, death rates and societal costs.
The U.S. Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favorably by a majority, Yes: 13, No: 1, that the benefits of the WATCHMAN Left Atrial Appendage Closure device outweigh the risks.
Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, announced today that the INTENSIA family of implantable cardioverter defibrillators and cardiac resynchronization therapy devices received CE (Conformité Européenne) mark approval. This family of devices includes the single-chamber INTENSIA VR, the dual-chamber INTENSIA DR and the INTENSIA SonR® CRT-D devices, all of which feature a DF-4 high voltage connector.
A researcher at the Cardiovascular Institute (CVI) at Rhode Island, The Miriam and Newport hospitals has found a link to human heart failure that if blocked, may reduce the risk of sudden cardiac death.
Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, announced today that it has received CE Mark approval for the Solo Smart stentless aortic valve.
A foundational study published in top biomedical journal PNAS (Proceedings of the National Academy of Sciences) this week by researchers at the University of Toronto's Institute of Biomaterials & Biomedical Engineering and the McEwen Centre for Regenerative Medicine have identified the optimal structure and cell ratio associated with heart function - and the discovery has already led the team to another research first: the engineering of the first-ever living, three-dimensional human arrhythmic tissue.
Results of a Johns Hopkins-led study have identified a possible link between a history of sudden drops in blood pressure and the most common form of irregular heartbeat.
A Johns Hopkins undergraduate biomedical engineering student team that devised a two-part system to improve the way life-saving shocks are delivered to hearts has earned first prize in the undergraduate division of the national Collegiate Inventors Competition.
ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today the establishment of the ZOLL Foundation, an independent entity organized for scientific and educational purposes.
Johns Hopkins undergraduate students have invented a system to shock a dangerously irregular heart back into normal rhythm more safely and effectively.
A Johns Hopkins undergraduate biomedical engineering student team that devised a two-part system to improve the way life-saving shocks are delivered to hearts earned first-prize in the undergraduate division of a national Collegiate Inventors Competition. In the graduate-level competition, Isaac Kinde, a Johns Hopkins medical student, received third-place honors for developing a test to detect ovarian and endometrial cancers as part of a team at the Johns Hopkins Kimmel Cancer Center.
An invention that strips cancer tumors' ability to hide from the body's immune system, and a better way to shock hearts back into their normal rhythm took top honors today at America's most prestigious collegiate inventing competition.
CardioInsight Technologies, Inc., a leading developer of non-invasive electrocardiographic mapping technology, announced today that it has completed a long-term strategic financing that provides the Company with an initial investment of $15 million.
The diagnosis and treatments of congenital heart disease have improved so much that many babies now born with heart defects can still look forward to a long and fulfilling life. Just two generations ago, the majority of babies born with heart defects died before their first birthday, but today many of these conditions can be corrected.
A multidisciplinary team of experts in heart failure, cardiac arrhythmia, and neurosurgery at The Mount Sinai Hospital are now testing nerve stimulation in the neck as a novel therapy for heart failure patients to potentially help relieve their debilitating symptoms of fatigue, shortness of breath, and heart arrhythmias, while reducing their hospitalizations.
Although an irregular heartbeat is a common malady in the United States, affecting an estimated 5 million people, the treatments for it are limited in scope and effectiveness.
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, today announced that it has concluded enrollment of its U.S. pivotal trial evaluating the HeartLight system, for the treatment of symptomatic paroxysmal AF.
Respicardia®, Inc., a developer of implantable therapies to improve respiratory and cardiovascular health, announced that it has been awarded the U.S. Healthcare Product of the Year by Acquisition International for the remede System, the first and only implantable device for the treatment of central sleep apnea.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.